Besides the above products mentioned, there are still 7 anti-PD-(L)1 antibodies in Phase III clinical trials, and lung cancer is still one of the important indications the most companies lay out.
Among the products in Phase III clinical trials:
The blockbuster imported product atezolizumab is expected to be applied for marketing in China in 2019, which has been approved as a first-line therapy for non-squamous NSCLC in the U.S., being an indication expansion of great significance.
Furthermore, several imported products that enter China are noteworthy.
1. Novartis’ anti-PD-1 antibody PDR001 has been started Phase II clinical trial in China;
2. The cemiplimab co-developed by Regeneron/Sanofi has just started IND in China;
3. The IND application for the anti-PD-L1/TGF-β M7824 developed by Merck KGaA has been approved.
Attached table: Development Progress of Main Anti-PD-(L)1antibodies in China